HAPP - Happiness Biotech Group Limited
| Previous Close | 4.2400 |
| Open | 4.2400 |
| Bid | 4.4100 x 900 |
| Ask | 4.4500 x 1000 |
| Day's Range | 4.0800 - 4.4500 |
| 52 Week Range | 3.9100 - 5.2400 |
| Volume | 35,170 |
| Avg. Volume | 43,754 |
| Market Cap | 110M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 5.41 |
| EPS (TTM) | 0.8140 |
| Earnings Date | Jan 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
- PR Newswire
Happiness Biotech Group Limited Announces Financial Results for the Six Months Ended September 30, 2019
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, today announced its unaudited financial results for the six months ended September 30, 2019. The financial results has been filed in a 6-K with the U.S. Securities and Exchange Commission (the "SEC") on January 10, 2020.
- PR Newswire
Happiness Biotech Announces the Opening of its First Experience Store in Hainan, China, introducing the Company's 31st Experience Store
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today the opening of its first experience store in Hainan, China, which is the Company's 31st experience store.
- GlobeNewswire
Univest Securities, LLC. Announces Closing of IPO for its Client Happiness Biotech Group Limited (NASDAQ: HAPP), Marking the Second Nasdaq IPO of Uinvest in 2019
Univest Securities, LLC, a FINRA and SIPC member full-service investment bank and securities broker-dealer firm, today announced the closing of previously announced the initial public offering (“IPO”) for its client Happiness Biotech Group Limited (“Happiness” or Nasdaq: HAPP), marking the second Nasdaq IPO underwritten as the lead-left underwriter and the sole book-runner by Uinvest in 2019. On a firm commitment basis, Univest sold, on behalf of Happiness, 2,000,000 shares of its ordinary shares at of $5.50 per share for a total of $11,000,000 in gross proceeds before fees and expenses.
- PR Newswire
Happiness Biotech Group Limited Announces Closing of US$11 Million Firm Commitment Initial Public Offering
NANPING, China, Oct. 30, 2019 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today the closing of previously announced a U.S. underwritten initial public offering ("Offering") of 2,000,000 ordinary shares at a price to the public of $5.50 per share. The Company received aggregate gross proceeds of $11 million from this Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares at the public offering price, less underwriting discounts.
- GlobeNewswire
Univest Securities, LLC. Announces Trading of IPO for its Client Happiness Biotech Group Limited (NASDAQ: HAPP), Marking the Second Nasdaq IPO and Listing Deal of Uinvest in 2019
Univest Securities, LLC, a FINRA and SIPIC member full-service investment bank and securities broker-dealer firm, today announced the pricing and trading of the initial public offering (“IPO”) for its client Happiness Biotech Group Limited (“Happiness”), marking the second Nasdaq IPO underwritten byUinvest in 2019. On a firm commitment basis, Univest sold, on behalf of Happiness, 2,000,000 shares of its ordinary shares at of $5.50 per share for a total of $11,000,000 in gross proceeds before fees and expenses.
- PR Newswire
Happiness Biotech Group Limited Announces Pricing of US$11 Million Firm Commitment Initial Public Offering
NANPING, China, Oct. 25, 2019 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company"), an innovative China-based nutraceutical and dietary supplements producer, announced today the pricing of a U.S. underwritten initial public offering ("Offering") of 2,000,000 ordinary shares at a price to the public of $5.50 per share. The Company expects to receive aggregate gross proceeds of $11 million from this Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares at the public offering price, less underwriting discounts.